After unsuccessfully pursuing treatment for his colorectal cancer at another medical institution in Atlanta, Jesse’s wife insisted they get a second opinion—which led him to Winship Cancer Institute of Emory University.
Jesse’s physician at Winship confirmed that he was “in pretty bad shape.” But this time his care team went an important step further with diagnostics and found that Jesse had a gene that meant the FDA-approved immunotherapy drug Keytruda could work well for him. The drug is particularly effective for people with Lynch syndrome-related colorectal cancer.
“I was probably two months into the therapy when we started getting results on the tumors and the cancer cells,” says Jesse. “The lymph nodes started looking better. And all of a sudden, the cancer in my stomach was completely eradicated. So, we knew we were on to something.”
Jesse’s sense of taste began to return, and so did his energy level. “All that process took probably a good seven, eight months,” he says. “And I finally got my body in good condition where it’s kind of back to normal.”
He’s back to work now after not being able to work because he was too weak. Although he’s still working on a limited schedule, he says it’s “a lot better than it was.”
Jesse is quick to credit his care team at Winship. “Everyone was involved,” he says. “Everybody was encouraging. It was a full-blown blitz. I hate to use a football term, but it was a blitz.”